Nitric oxide (NO) and its synthases attained celebrity among oncologists because of the evidence of frequent deregulation of NO production in several tumors, including prostate cancer (PCa, [1], [2], [3], and of the discovery of a key role played by the endothelial NOS (eNOS) in tumor maintenance and progression [1], [3], [4]. This evidence concerns the gene NOS3 and neoplasm.